Valuation: Fortress Biotech, Inc.

Market Cap 82.04M 71.1M 67.2M 61.01M 114M 7.87B 115M 802M 310M 3.99B 308M 301M 12.72B P/E 2026 *
0.96x
P/E 2027 * -2.46x
Enterprise Value 82.04M 71.1M 67.2M 61.01M 114M 7.87B 115M 802M 310M 3.99B 308M 301M 12.72B EV / Sales 2026 *
1.04x
EV / Sales 2027 * 0.72x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-1.20%
1 week-6.46%
Current month-10.05%
1 month-16.04%
3 months-16.04%
6 months-20.39%
Current year-32.79%
1 week 2.41
Extreme 2.41
2.62
1 month 2.41
Extreme 2.41
2.99
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
5.39
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 36 16/08/2022
Director of Finance/CFO 51 22/02/2012
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap. Importance
1/4/26 Free

Chief Financial Officer

2,967 0.0096%
18/3/26 Free

Chief Executive Officer

475,424 1.5318%
18/3/26 Free

Director

475,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-6.46%-28.28%-53.14% 82.04M
+0.06%-4.09%+34.70%-5.93% 77.35B
+1.81%+4.76%-11.69%-33.17% 59.58B
+1.29%+7.38%+486.23%+27.08% 58.14B
-0.21%-2.96%-11.54%+25.36% 47.62B
-1.81%+0.73%+1.08%+144.77% 45.34B
-0.07%+2.51%+50.34%-15.22% 31.92B
+2.47%-1.00%+48.69%+99.44% 25.29B
+2.02%+1.80%-0.47%+141.03% 20.88B
-0.05%-0.86%+57.38%+95.99% 15.64B
Average +0.22%-0.51%+62.64%+42.62% 38.18B
Weighted average by Cap. +0.19%+0.43%+87.68%+35.05%

Financials

2026 *2027 *
Net sales 78.79M 68.28M 64.54M 58.59M 110M 7.56B 110M 770M 298M 3.83B 296M 289M 12.22B 113M 98.14M 92.76M 84.21M 158M 10.86B 159M 1.11B 428M 5.51B 425M 416M 17.56B
Net income 88.25M 76.47M 72.28M 65.62M 123M 8.47B 124M 863M 333M 4.29B 331M 324M 13.69B -37.81M -32.77M -30.97M -28.12M -52.7M -3.63B -53.02M -370M -143M -1.84B -142M -139M -5.86B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
16/09/26 USD 2.460 -1.20% 352,885
15/09/26 USD 2.490 -1.58% 225,323
14/09/26 USD 2.530 +0.40% 226,477
11/09/26 USD 2.520 -1.95% 209,700
10/09/26 USD 2.570 -2.28% 315,547
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.460USD
Average target price
11.00USD
Spread / Average Target
+347.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!